Cargando…
Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376763/ https://www.ncbi.nlm.nih.gov/pubmed/22720170 http://dx.doi.org/10.5402/2012/763159 |
_version_ | 1782235864162631680 |
---|---|
author | Sager, Cristian Burek, Carol Durán, Victor Corbetta, Juan Pablo Weller, Santiago Juan, Bortagaray López, Juan Carlos |
author_facet | Sager, Cristian Burek, Carol Durán, Victor Corbetta, Juan Pablo Weller, Santiago Juan, Bortagaray López, Juan Carlos |
author_sort | Sager, Cristian |
collection | PubMed |
description | When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse effects. Due to its transitory effect, it is necessary to repeat the injections in order to sustain its therapeutic effect. In these review article we talk about Mechanism of Action, Indications, effects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also, we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients younger than 18 years of age and reports written in English in the past ten years. |
format | Online Article Text |
id | pubmed-3376763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-33767632012-06-20 Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A Sager, Cristian Burek, Carol Durán, Victor Corbetta, Juan Pablo Weller, Santiago Juan, Bortagaray López, Juan Carlos ISRN Urol Review Article When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse effects. Due to its transitory effect, it is necessary to repeat the injections in order to sustain its therapeutic effect. In these review article we talk about Mechanism of Action, Indications, effects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also, we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients younger than 18 years of age and reports written in English in the past ten years. International Scholarly Research Network 2012-06-07 /pmc/articles/PMC3376763/ /pubmed/22720170 http://dx.doi.org/10.5402/2012/763159 Text en Copyright © 2012 Cristian Sager et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Sager, Cristian Burek, Carol Durán, Victor Corbetta, Juan Pablo Weller, Santiago Juan, Bortagaray López, Juan Carlos Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title | Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title_full | Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title_fullStr | Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title_full_unstemmed | Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title_short | Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A |
title_sort | pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376763/ https://www.ncbi.nlm.nih.gov/pubmed/22720170 http://dx.doi.org/10.5402/2012/763159 |
work_keys_str_mv | AT sagercristian pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT burekcarol pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT duranvictor pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT corbettajuanpablo pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT wellersantiago pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT juanbortagaray pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea AT lopezjuancarlos pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea |